The key finding
A 2025 review in Critical Reviews in Oncology/Hematology highlights that colorectal cancer (CRC) remains stubbornly resistant to immune checkpoint blockade (ICB) therapy — a treatment that works well in many other cancers. The authors argue that gut microbiota, particularly how gut bacteria metabolize the amino acid tryptophan, is linked to ICB efficacy and deserves targeted investigation in CRC. Research in this area lags behind other cancer types, and the review proposes specific strategies to bridge that gap, including diversifying clinical trial recruitment and using interdisciplinary methods to design prebiotic-based interventions.
What the study looked like
This is not a new experimental study but rather a critical review synthesizing existing literature on gut microbiota and immunotherapy outcomes in colorectal cancer. The authors examined preclinical studies (animal models and lab experiments), clinical trials involving fecal microbiota transplantation, and emerging technologies for microbiome analysis. They focused on work exploring how microbial communities and their metabolic byproducts influence immune checkpoint inhibitors — drugs that “unblock” the immune system to attack cancer. The review identifies key bottlenecks: CRC-specific microbiome research is underdeveloped compared to melanoma or lung cancer, and clinical cohorts are often too narrow in scope.
Why researchers think this happened
Immune checkpoint blockade works by removing molecular “brakes” on T cells, enabling them to recognize and destroy cancer. However, CRC tumors are frequently “cold” — meaning fewer immune cells infiltrate them, making ICB less effective. Gut bacteria produce metabolites from dietary components like tryptophan, and these metabolites (such as indole derivatives) can modulate immune cell activity and inflammation. The review authors hypothesize that tryptophan metabolism by gut microbes specifically influences the tumor immune microenvironment in CRC, potentially explaining why some patients respond to ICB and others do not. Prior work in melanoma and other cancers has shown that certain bacterial species correlate with better ICB outcomes, but the microbial signatures in CRC appear distinct and less studied.
How to read this carefully
This is a review, not a controlled trial, so it reflects expert opinion and synthesis rather than new experimental data. The tryptophan–microbiota link is promising but still correlational; no studies yet prove that altering tryptophan metabolism directly causes improved ICB response in CRC patients. The authors call for more research, acknowledging that current evidence is limited by small sample sizes, geographic homogeneity in trial cohorts, and lack of mechanistic clarity. Fecal microbiota transplantation (FMT) trials in CRC are rare, and results vary. Readers should not interpret this as evidence that probiotics or dietary tryptophan supplements improve cancer outcomes — those claims are unsupported.
What this means for everyday life
If you or someone you know has colorectal cancer, this review underscores that immunotherapy resistance is a major challenge — but gut health may be part of the puzzle. The role of diet (especially foods high in tryptophan, like turkey, eggs, and seeds) and gut bacteria in cancer treatment is an active research frontier, not yet ready for clinical application. Given the link between microbiota and immune function, maintaining a diverse gut microbiome through fiber-rich foods could theoretically support overall health, though no direct connection to CRC immunotherapy success is established. The review’s call for interdisciplinary research — blending microbiology, oncology, and computational modeling — suggests that personalized microbiome interventions might one day improve treatment. For now, it’s a reminder that cancer therapy is complex and that the trillions of microbes in our gut may influence outcomes in ways we’re only beginning to understand.